Drug Details

General Information of the Drug (ID: DR4313)
Name
Ertugliflozin
Synonyms
Ertugliflozin; 1210344-57-2; PF-04971729; Steglatro; PF04971729; UNII-6C282481IP; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; CHEMBL1770248; 1210344-57-2 (free base); 6C282481IP; (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; PF 04971729; Ertugliflozin [USAN:INN]; (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol; MK-8835; Tube108; Ertugliflozin (USAN/INN); PF 04971729-00; PF-04971729-00; cc-212; SCHEMBL181047; GTPL8376; PF-04971729;Ertugliflozin; DTXSID40153120; EX-A407; AMY32613; ABP000359; BDBM50342885; MFCD21609259; s5413; ZINC68197809; AKOS025404928; CCG-269087; CS-0976; DB11827; SB11082; 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol; AC-29007; AS-35204; beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-; HY-15461; Y0303; D10313; W-5850; J-504029; PF-04971729/PF04971729/; Q27077223; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,5S)-1-(Hydroxymethyl)-5-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6,8-dioxabicyclo[3.2.1]octane-2beta,3alpha,4beta-triol
    Click to Show/Hide
Molecular Type
Small molecule
Disease Type 2 diabetes mellitus [ICD-11: 5A11] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 1193 mcgh/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 268 mcg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.5-1.5 h
Bioavailability
The bioavailability of drug is 70-90%
Clearance
The total plasma clearance of drug is 178.7 mL/min
Elimination
The total recovery of ertugliflozin was 91% and this elimination route is distributed in a ratio of 50% in the urine and 41% in feces
Half-life
The concentration or amount of drug in body reduced by one-half in 11 - 17 hours
Metabolism
The drug is metabolized via the liver
Vd
The volume of distribution (Vd) of drug is 215.3 L
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C22H25ClO7
PubChem CID
44814423
Canonical SMILES
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl
InChI
1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
InChIKey
MCIACXAZCBVDEE-CUUWFGFTSA-N
CAS Number
CAS 1210344-57-2
TTD Drug ID
D0Q3VE
DrugBank ID
DB11827
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Metformin      Galega officinalis     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical trial
                    Experimental
                    Result(s)		 The fixed-dose combination of ertugliflozin with metformin is an effective combination that is conveniently administered and may improve medication adherence and persistence.
Target and Pathway
Target(s) Sodium/glucose cotransporter 2 (SGLT2)  Molecule Info  [3]
Reactome Hexose transport Click to Show/Hide
2 Na+-dependent glucose transporters
3 Inositol transporters
WikiPathways NRF2 pathway Click to Show/Hide
2 Nuclear Receptors Meta-Pathway
3 Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Reference 1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
Reference 2 Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2019 Mar;14(2):75-83.
Reference 3 Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
 Download Picture         KEGG Link